Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

A. Johnson, J.; Gong, Li; Whirl‐Carrillo, Michelle; F. Gage, Brian; A. Scott, Stuart; Michael Stein, C.; L. Anderson, J.; E. Kimmel, Stephen; T M Lee, M; Pirmohamed, Munir; Wadelius, Mia; E. Klein, Teri; B. Altman, Russ

doi:10.1038/clpt.2011.185

Public

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

Published in Clinical Pharmacology & Therapeutics • Sep 7, 2011

Authors:

J. A. Johnson

Li Gong

Michelle Whirl‐Carrillo

Abstract

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the dose required to achieve target anticoagulation. Common genetic variants in the cytochrome P450-2C9 (CYP2C9) and vitamin K-epoxide reductase complex (VKORC1) enzymes, in addition to know...

Subject

VKORC1

CYP2C9

Warfarin

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!